110 related articles for article (PubMed ID: 17545628)
1. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression.
Kondo T; Zheng L; Liu W; Kurebayashi J; Asa SL; Ezzat S
Cancer Res; 2007 Jun; 67(11):5461-70. PubMed ID: 17545628
[TBL] [Abstract][Full Text] [Related]
2. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.
Kondo T; Zhu X; Asa SL; Ezzat S
Clin Cancer Res; 2007 Aug; 13(16):4713-20. PubMed ID: 17699848
[TBL] [Abstract][Full Text] [Related]
3. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
4. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; RodrÃguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
6. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
7. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor-2 up-regulates the expression of nestin through the Ras-Raf-ERK-Sp1 signaling axis in C6 glioma cells.
Chang KW; Huang YL; Wong ZR; Su PH; Huang BM; Ju TK; Yang HY
Biochem Biophys Res Commun; 2013 May; 434(4):854-60. PubMed ID: 23611784
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
12. The roles of FGF signaling in germ cell migration in the mouse.
Takeuchi Y; Molyneaux K; Runyan C; Schaible K; Wylie C
Development; 2005 Dec; 132(24):5399-409. PubMed ID: 16291796
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone inhibits basic fibroblast growth factor-stimulated gastric epithelial cell proliferation.
Luo JC; Lin HY; Lu CL; Wang LY; Chang FY; Lin HC; Huang YC; Ng KM; Chi CW; Lee SD
Biochem Pharmacol; 2008 Oct; 76(7):841-9. PubMed ID: 18692028
[TBL] [Abstract][Full Text] [Related]
14. Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth.
Liu Z; Neiss N; Zhou S; Henne-Bruns D; Korc M; Bachem M; Kornmann M
Cancer Res; 2007 Mar; 67(6):2712-9. PubMed ID: 17363592
[TBL] [Abstract][Full Text] [Related]
15. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
16. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
Arthan D; Hong SK; Park JI
Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
[TBL] [Abstract][Full Text] [Related]
17. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
18. Spry2 expression correlates with BRAF mutation in thyroid cancer.
Xu L; Zhou JL; Cohen M; Bar-Sagi D; Patel KN
Surgery; 2010 Dec; 148(6):1282-7; discussion 1287. PubMed ID: 21134562
[TBL] [Abstract][Full Text] [Related]
19. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells.
Feng S; Wang F; Matsubara A; Kan M; McKeehan WL
Cancer Res; 1997 Dec; 57(23):5369-78. PubMed ID: 9393762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
